Cyclosporine

Generic Name: Cyclosporine

Brand Names: Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis

Drug Type: Small Molecule

Chemical Formula: C_₆₂H_₁₁₁N_₁₁O_₁₂

CAS Number: 59865-13-3

Unique Ingredient Identifier: 83HN0GTJ6D

Background: Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...

Indication: Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...

Associated Conditions: Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production

Associated Therapies: -

Clinical Trials

Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action

Phase 2

Completed

Conditions: Interstitial Cystitis

Interventions: Drug: Cyclosporine

First Posted Date: 2013-11-25

Last Posted Date: 2017-04-19

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 26

Registration Number: NCT01990898

Locations: 🇺🇸
Cleveland Clinic - Main Campus Only, Cleveland, Ohio, United States

Gengraf Conversion Study in Stable Renal Allograft Transplant Recipients

Phase 4

Completed

Conditions: End Stage Renal Failure

Interventions: Drug: Gengraf® capsule containing 25mg or 100mg cyclosporine
Drug: Neoral

First Posted Date: 2013-11-21

Last Posted Date: 2013-11-21

Lead Sponsor: Penang Hospital, Malaysia

Target Recruit Count: 106

Registration Number: NCT01990118

Locations: 🇲🇾
Clinical Research Centre, Penang Hospital, George Town, Penang, Malaysia

A Study of Baricitinib and Ciclosporin in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Baricitinib
Drug: Ciclosporin

First Posted Date: 2013-10-23

Last Posted Date: 2017-06-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 18

Registration Number: NCT01968057

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom

Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

Phase 1

Terminated

Conditions: Stage II Multiple Myeloma
Stage III Multiple Myeloma
Refractory Multiple Myeloma
Stage I Multiple Myeloma

Interventions: Drug: fludarabine phosphate
Radiation: total-body irradiation
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Drug: cyclosporine
Drug: mycophenolate mofetil
Drug: bortezomib
Drug: lenalidomide
Other: laboratory biomarker analysis

First Posted Date: 2013-10-07

Last Posted Date: 2017-02-17

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 8

Registration Number: NCT01954784

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation

Phase 2

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: Simeprevir
Drug: Daclatasvir
Drug: Ribavirin
Drug: Cyclosporine
Drug: Tacrolimus

First Posted Date: 2013-09-10

Last Posted Date: 2018-11-21

Lead Sponsor: Janssen R&D Ireland

Target Recruit Count: 35

Registration Number: NCT01938625

12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients

Phase 3

Completed

Conditions: Kidney Transplantation
Renal Transplantation

Interventions: Drug: Everolimus
Drug: Enteric Coated Mycophenolate Sodium (EC-MPS)
Drug: Tacrolimus
Drug: Cyclosporin A
Drug: Mycophenolate mofetil (MMF)
Drug: Corticosteroids
Drug: Simulect

First Posted Date: 2013-04-30

Last Posted Date: 2017-05-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 612

Registration Number: NCT01843348

Locations: 🇩🇪
Novartis Investigative Site, Tübingen, Germany

A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based

Phase 3

Completed

Conditions: Kidney Transplantation

Interventions: Drug: Tacrolimus
Drug: Belatacept
Drug: Cyclosporine

First Posted Date: 2013-03-29

Last Posted Date: 2021-01-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 446

Registration Number: NCT01820572

Locations: 🇺🇸
Transplant Research Institute (PI Address), Los Angeles, California, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Saint Barnabas Medical Center, Livingston, New Jersey, United States

and more 59 locations